Tactical Therapeutics
Tactical Therapeutics, Inc has developed a brain penetrant oral drug Carboxyamidotriazole Orotate (CTO) to treat glioblastoma. CTO, which inhibits Ca2+ channels and Ca2+ signaling demonstrated Safety and Efficacy in 26 recurrent GBM patients when given with temozolomide (6 PRs and 1CR), and 15 newly diagnosed GBM patients when added to SOC, resulting in median PFS of 17.9 months, and OS of 37.8 months, suggesting inhibiting Ca2+ with CTO provides a promising approach to treat GBM.
